Kynurenergic Manipulations Influence Excitatory Synaptic Function and Excitotoxic Vulnerability in the Rat Hippocampus in Vivo
Overview
Authors
Affiliations
Competing enzymatic mechanisms degrade the tryptophan metabolite L-kynurenine to kynurenate, an inhibitory and neuroprotective compound, and to the neurotoxins 3-hydroxykynurenine and quinolinate. Kynurenine 3-hydroxylase inhibitors such as PNU 156561 shift metabolism towards enhanced kynurenate production, and this effect may underlie the recently discovered anticonvulsant and neuroprotective efficacy of these drugs. Using electrophysiological and neurotoxicological endpoints, we now used PNU 156561 as a tool to examine the functional interplay of kynurenate, 3-hydroxykynurenine and quinolinate in the rat hippocampus in vivo. First, population spike amplitude in area CA1 and the extent of quinolinate-induced excitotoxic neurodegeneration were studied in animals receiving acute or prolonged intravenous infusions of L-kynurenine, PNU 156561, (L-kynurenine+PNU 156561) or kynurenate. Only the latter two treatments, but not L-kynurenine or PNU 156561 alone, caused substantial inhibition of evoked responses in area CA1, and only prolonged (3h) infusion of (L-kynurenine+PNU 156561) or kynurenate was neuroprotective. Biochemical analyses in separate animals revealed that the levels of kynurenate attained in both blood and brain (hippocampus) were essentially identical in rats receiving extended infusions of L-kynurenine alone or (L-kynurenine+PNU 156561) (4 and 7microM, respectively, after an infusion of 90 or 180min). However, addition of the kynurenine 3-hydroxylase inhibitor resulted in a significant decrement in the formation of 3-hydroxykynurenine and quinolinate in both blood and brain. These data suggest that the ratio between kynurenate and 3-hydroxykynurenine and/or quinolinate in the brain is a critical determinant of neuronal excitability and viability. The anticonvulsant and neuroprotective potency of kynurenine 3-hydroxylase inhibitors may therefore be due to the drugs' dual action on both branches of the kynurenine pathway of tryptophan degradation.
Tanaka M, Szabo A, Vecsei L Int J Mol Sci. 2024; 25(23).
PMID: 39684480 PMC: 11640972. DOI: 10.3390/ijms252312767.
Activated Tryptophan-Kynurenine metabolic system in the human brain is associated with learned fear.
Battaglia M, Di Fazio C, Battaglia S Front Mol Neurosci. 2023; 16:1217090.
PMID: 37575966 PMC: 10416643. DOI: 10.3389/fnmol.2023.1217090.
Cellular Localization of Kynurenine 3-Monooxygenase in the Brain: Challenging the Dogma.
Sathyasaikumar K, la Cruz V, Pineda B, Vazquez Cervantes G, Ramirez Ortega D, Donley D Antioxidants (Basel). 2022; 11(2).
PMID: 35204197 PMC: 8868204. DOI: 10.3390/antiox11020315.
Mithaiwala M, Santana-Coelho D, Porter G, OConnor J Cells. 2021; 10(6).
PMID: 34205235 PMC: 8235708. DOI: 10.3390/cells10061548.
Kynurenines in the Pathogenesis of Multiple Sclerosis: Therapeutic Perspectives.
Biernacki T, Sandi D, Bencsik K, Vecsei L Cells. 2020; 9(6).
PMID: 32604956 PMC: 7349747. DOI: 10.3390/cells9061564.